Evaxion A/S (NASDAQ:EVAX) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Evaxion A/S (NASDAQ:EVAX) to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Evaxion A/S has an average rating of “Moderate Buy” and an average price target of $11.25.

Evaxion A/S Price Performance

Shares of Evaxion A/S stock traded down $0.03 during midday trading on Friday, hitting $2.74. 46,577 shares of the company were exchanged, compared to its average volume of 138,993. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The firm has a market cap of $24.71 million, a P/E ratio of -2.26 and a beta of 0.60. Evaxion A/S has a 52 week low of $2.65 and a 52 week high of $6.92. The firm has a 50 day simple moving average of $3.13 and a 200-day simple moving average of $3.43.

Hedge Funds Weigh In On Evaxion A/S

A number of large investors have recently added to or reduced their stakes in EVAX. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Evaxion A/S in the 1st quarter valued at about $112,000. Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S during the first quarter worth about $146,000. Finally, Rathbones Group PLC acquired a new position in shares of Evaxion A/S during the first quarter worth about $170,000. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.